Ferguson Wellman Capital Management Inc. cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 128,375 shares of the biopharmaceutical company’s stock after selling 1,815 shares during the quarter. Ferguson Wellman Capital Management Inc.’s holdings in Pfizer were worth $4,712,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of PFE. BlackRock Inc. boosted its stake in Pfizer by 0.8% in the 2nd quarter. BlackRock Inc. now owns 427,534,404 shares of the biopharmaceutical company’s stock worth $13,980,372,000 after purchasing an additional 3,464,207 shares in the last quarter. State Street Corp raised its holdings in Pfizer by 0.3% in the first quarter. State Street Corp now owns 292,621,398 shares of the biopharmaceutical company’s stock worth $9,551,162,000 after buying an additional 830,299 shares during the last quarter. Capital World Investors raised its holdings in Pfizer by 19.1% in the first quarter. Capital World Investors now owns 224,808,113 shares of the biopharmaceutical company’s stock worth $7,337,737,000 after buying an additional 36,092,723 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Pfizer by 1.8% in the second quarter. Bank of New York Mellon Corp now owns 57,111,863 shares of the biopharmaceutical company’s stock worth $1,867,559,000 after buying an additional 1,024,264 shares in the last quarter. Finally, Sanders Capital LLC grew its holdings in shares of Pfizer by 5.0% during the second quarter. Sanders Capital LLC now owns 28,282,011 shares of the biopharmaceutical company’s stock valued at $1,046,595,000 after buying an additional 1,349,012 shares during the last quarter. Hedge funds and other institutional investors own 69.08% of the company’s stock.

PFE has been the topic of several analyst reports. SVB Leerink upped their price objective on Pfizer from $39.00 to $42.00 and gave the company a “market perform” rating in a research report on Wednesday, July 29th. UBS Group upped their price target on Pfizer from $37.00 to $39.00 and gave the company a “neutral” rating in a report on Wednesday, July 29th. Morgan Stanley increased their price objective on Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. Piper Sandler boosted their target price on Pfizer from $18.50 to $24.00 in a research report on Friday, June 26th. Finally, ValuEngine downgraded shares of Pfizer from a “hold” rating to a “sell” rating in a report on Thursday, July 30th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $39.64.

In related news, Director Ronald E. Blaylock purchased 13,000 shares of Pfizer stock in a transaction on Thursday, August 6th. The stock was acquired at an average price of $38.55 per share, for a total transaction of $501,150.00. Following the completion of the transaction, the director now directly owns 4,000 shares in the company, valued at approximately $154,200. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 0.08% of the stock is currently owned by insiders.

Shares of NYSE:PFE opened at $37.95 on Friday. The company has a quick ratio of 1.16, a current ratio of 1.42 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $210.88 billion, a PE ratio of 15.06, a price-to-earnings-growth ratio of 2.91 and a beta of 0.67. The firm’s 50 day moving average price is $36.59 and its 200-day moving average price is $36.32. Pfizer Inc. has a twelve month low of $27.88 and a twelve month high of $40.97.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.14. The business had revenue of $11.80 billion during the quarter, compared to analysts’ expectations of $11.55 billion. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The firm’s revenue was down 11.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.80 earnings per share. Analysts expect that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, November 6th will be given a dividend of $0.38 per share. The ex-dividend date is Thursday, November 5th. This represents a $1.52 annualized dividend and a yield of 4.01%. Pfizer’s dividend payout ratio (DPR) is presently 51.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: Recession

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.